Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Other Operating Expenses (2019 - 2024)

Addex Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at $7.5 million for Q4 2024.

  • On a quarterly basis, Other Operating Expenses fell 8.95% to $7.5 million in Q4 2024 year-over-year; TTM through Sep 2025 was $7.5 million, a 8.95% decrease, with the full-year FY2025 number at -$10218.3, up 95.35% from a year prior.
  • Other Operating Expenses came in at $7.5 million for Q4 2024, up from $0.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $17.7 million in Q4 2020, with the low at -$0.0 in Q3 2020.
  • Historically, Other Operating Expenses has averaged $7.6 million across 5 years, with a median of $7.5 million in 2024.
  • Biggest five-year swings in Other Operating Expenses: soared 50.0% in 2020 and later crashed 52.43% in 2023.
  • Year by year, Other Operating Expenses stood at $17.7 million in 2020, then fell by 0.22% to $17.7 million in 2021, then dropped by 2.2% to $17.3 million in 2022, then tumbled by 52.43% to $8.2 million in 2023, then decreased by 8.95% to $7.5 million in 2024.
  • Business Quant data shows Other Operating Expenses for ADXN at $7.5 million in Q4 2024, $0.0 in Q1 2024, and $8.2 million in Q4 2023.